Teva to sell generic version of Novo Nordiskās diabeticĀ drug in US
Israelās Teva Pharmaceuticals will start selling a generic version of Novo Nordiskās type 2 diabetic drug Victoza in the US market.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Israelās Teva Pharmaceuticals will start selling a generic version of Novo Nordiskās type 2 diabetic drug Victoza in the US market.
Novo Nordisk, a Danish pharmaceutical multinational, will invest $4.1 billion to build a new factory in the US to make obesity and chronic.
The World Health Organization has issued a medical product alert on falsified semaglutides, an active ingredient in Ozempic, a diabetic drug made by.
The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA refused approval for a once-weekly jab to control blood sugar levels in people.
HQ Team May 2, 2024: Novo Nordisk, Europeās most valuable company, has raised its 2024 revenue outlook on the back of its popular.
US-based biotechnology company Viking Therapeutics Inc., reported āpositiveā results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.
HQ Team March 25, 2024: Novo Nordisk, one of the worldās most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises.
HQ Team March 11, 2024: Danish drugmaker Novo Nordiskās oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company.
HQ Team March 6, 2024: Novo Nordiskās diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney deaths in 24%.
HQ Team February 5, 2024: Novo Nordisk will acquire three manufacturing sites in an $11bn deal to expand its production of weightless drugs.